Tagged with manufacturing

USA Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration is putting pressure on pharma to situate production on US soil. This pressure is predominantly taking the form of economic…

Denmark Drawn from Healthcare & Life Sciences Review Denmark 2025, this selection captures the major forces now reshaping one of Europe’s most dynamic life science hubs. From Denmark’s bid to double the sector’s economic weight by 2030, to its sweeping “Health Closer to You” reform, biotech surge, clinical-trials strategy, and evolving…

Mexico Adriana Eguia Alaniz is President of Tijuana EDC, leading efforts to diversify and strengthen the region’s economy. Under her leadership, Tijuana has strengthened its role as a major medical device export hub, with 55,000 workers, $3B in exports, and 40+ global companies. Her priorities include cross-border speed-to-market, supply chain resilience,…

LatAm Gianclaudio Broggi is CEO and chairman of Megalabs, one of Latin America’s largest biopharma organisations with operations spanning more than 20 countries and a workforce exceeding 9,000 employees. With over two decades at the company, he has been instrumental in its transformation from a 120 million USD enterprise into a…

LatAm Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and routine immunisation disrupted by pandemic aftershocks, even long-protected regions are witnessing a resurgence in preventable diseases. In Latin America, where…

USA Norman Stoffregen, SVP and Site Head at Enzene Inc., explains how the US arm of India’s Enzene Biosciences is introducing its cost-efficient, continuous manufacturing model to the US CDMO market. With a state-of-the-art facility in Hopewell, New Jersey, Enzene supports mid-sized biopharma clients with flexible, small-footprint biologics production. By combining…

Switzerland Marcel Imwinkelried, CEO of Siegfried, leads a CDMO specialising in small molecules with comprehensive global manufacturing capabilities. His “Evolve Plus” strategy focuses on operational excellence, selective biologics growth, and disciplined acquisitions to ensure sustainable expansion. Under his leadership, Siegfried prioritises innovation, sustainability, and talent development to deliver lasting value to…

Europe Europe has a plasma problem. The continent is over-reliant on the US for plasma – donated, purified human blood liquid – which is a key component in several lifesaving drugs for immunity, bleeding, critical care, and rare disorders.   The Donor Dilemma One explanation for these shortages is the lack…

France With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR 750 million investment in a new industrial site and a unique public health mandate, the state-owned player is not just…

Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…

France Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial investments exceeding EUR 2.3 billion, the establishment of France as a global manufacturing hub for next-generation diabetes and obesity treatments,…

Switzerland Marie Leblanc brings a distinctive combination of scientific rigor and commercial acumen to her role as Executive Vice President of Life Sciences at Biosynth, drawing from an 18-year tenure at Lonza where she witnessed the evolution of the contract development and manufacturing organisation (CDMO) industry from a traditional service provider…